Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The vitreoretinal interface is the highly specialized zone where the vitreous gel meets the internal limiting membrane (ILM) of the retina. It is composed of the posterior vitreous cortex, the ILM, and an extracellular matrix "glue" rich in fibronectin, laminin, and various collagens, which mediate adhesion between the vitreous body and the retinal surface[1][4][7]. The strength and configuration of this interface can vary with age, topography, and pathological conditions, and abnormal traction or separation at the VRI underlies diseases such as macular hole, vitreomacular traction, and certain forms of diabetic retinopathy[4][6][7]. The VRI is a region, not a protein or gene, and direct pharmacological interventions target its extracellular matrix components rather than a canonical molecular target.
Enzymatic degradation of extracellular matrix proteins (fibronectin, laminin, collagen) to induce posterior vitreous detachment
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vitreoretinal interface.